Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2011 Jan 12;305(2):183-90.
doi: 10.1001/jama.2010.1977.

Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies

Lisa G Rider  1 , Frederick W Miller
Affiliations
Case Reports

Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies

Lisa G Rider et al. JAMA. .

Abstract

The idiopathic inflammatory myopathies or myositis syndromes (the most common forms are polymyositis, dermatomyositis, and inclusion body myositis) are systemic autoimmune diseases defined by chronic muscle weakness and inflammation of unknown etiology and result in significant morbidity and mortality. Research suggests that categorizing heterogeneous myositis syndromes into mutually exclusive and stable phenotypes by using clinical and immune response features is useful for predicting clinical signs and symptoms, associated genetic and environmental risk factors, and responses to therapy and prognosis. Knowledge of myositis phenotypes should enhance clinicians' ability to recognize and manage these rare disorders.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Characteristic findings associated with clinical and autoantibody phenotypes in myositis
A. Heliotrope, malar rash and facial erythema in pattern of photosensitivity, as seen in this 11-year-old juvenile dermatomyositis patient with anti-p155 autoantibodies. B. Interstitial lung disease, defined by high-resolution computed tomographic (CT) scanning, is seen frequently in patients with polymyositis, as well as with the anti-synthetase autoantibody phenotype. More recently, rapidly progressive interstitial lung disease has been associated with the CADM-140 autoantibody. The chest CT scan depicted here is from a 55 year old female patient with anti-Jo-1 autoantibodies and interstitial lung disease. C. Dystrophic calcification, as present around the elbow and forearm here in this 10.5-year-old girl with juvenile dermatomyositis and anti-MJ autoantibodies, is seen in up to 25% of juvenile-onset dermatomyositis and less frequently in adult-onset disease. Calcinosis is present in > 60% of patients with the anti-MJ autoantibody phenotype. D. Lipodystrophy, loss of subcutaneous fat with frequently associated insulin resistance, diabetes and hypertriglyceridemia, are associated with juvenile-onset dermatomyositis. Generalized lipodystrophy, a widespread loss of fat from the trunk and extremities, has been associated with anti-p155 autoantibodies. A loss of fat from the arm is seen in this 20-year-old woman with juvenile onset dermatomyositis since age 8 years, who has anti-p155 autoantibodies and lipodystrophy.
Figure 1
Figure 1. Characteristic findings associated with clinical and autoantibody phenotypes in myositis
A. Heliotrope, malar rash and facial erythema in pattern of photosensitivity, as seen in this 11-year-old juvenile dermatomyositis patient with anti-p155 autoantibodies. B. Interstitial lung disease, defined by high-resolution computed tomographic (CT) scanning, is seen frequently in patients with polymyositis, as well as with the anti-synthetase autoantibody phenotype. More recently, rapidly progressive interstitial lung disease has been associated with the CADM-140 autoantibody. The chest CT scan depicted here is from a 55 year old female patient with anti-Jo-1 autoantibodies and interstitial lung disease. C. Dystrophic calcification, as present around the elbow and forearm here in this 10.5-year-old girl with juvenile dermatomyositis and anti-MJ autoantibodies, is seen in up to 25% of juvenile-onset dermatomyositis and less frequently in adult-onset disease. Calcinosis is present in > 60% of patients with the anti-MJ autoantibody phenotype. D. Lipodystrophy, loss of subcutaneous fat with frequently associated insulin resistance, diabetes and hypertriglyceridemia, are associated with juvenile-onset dermatomyositis. Generalized lipodystrophy, a widespread loss of fat from the trunk and extremities, has been associated with anti-p155 autoantibodies. A loss of fat from the arm is seen in this 20-year-old woman with juvenile onset dermatomyositis since age 8 years, who has anti-p155 autoantibodies and lipodystrophy.
Figure 1
Figure 1. Characteristic findings associated with clinical and autoantibody phenotypes in myositis
A. Heliotrope, malar rash and facial erythema in pattern of photosensitivity, as seen in this 11-year-old juvenile dermatomyositis patient with anti-p155 autoantibodies. B. Interstitial lung disease, defined by high-resolution computed tomographic (CT) scanning, is seen frequently in patients with polymyositis, as well as with the anti-synthetase autoantibody phenotype. More recently, rapidly progressive interstitial lung disease has been associated with the CADM-140 autoantibody. The chest CT scan depicted here is from a 55 year old female patient with anti-Jo-1 autoantibodies and interstitial lung disease. C. Dystrophic calcification, as present around the elbow and forearm here in this 10.5-year-old girl with juvenile dermatomyositis and anti-MJ autoantibodies, is seen in up to 25% of juvenile-onset dermatomyositis and less frequently in adult-onset disease. Calcinosis is present in > 60% of patients with the anti-MJ autoantibody phenotype. D. Lipodystrophy, loss of subcutaneous fat with frequently associated insulin resistance, diabetes and hypertriglyceridemia, are associated with juvenile-onset dermatomyositis. Generalized lipodystrophy, a widespread loss of fat from the trunk and extremities, has been associated with anti-p155 autoantibodies. A loss of fat from the arm is seen in this 20-year-old woman with juvenile onset dermatomyositis since age 8 years, who has anti-p155 autoantibodies and lipodystrophy.
Figure 1
Figure 1. Characteristic findings associated with clinical and autoantibody phenotypes in myositis
A. Heliotrope, malar rash and facial erythema in pattern of photosensitivity, as seen in this 11-year-old juvenile dermatomyositis patient with anti-p155 autoantibodies. B. Interstitial lung disease, defined by high-resolution computed tomographic (CT) scanning, is seen frequently in patients with polymyositis, as well as with the anti-synthetase autoantibody phenotype. More recently, rapidly progressive interstitial lung disease has been associated with the CADM-140 autoantibody. The chest CT scan depicted here is from a 55 year old female patient with anti-Jo-1 autoantibodies and interstitial lung disease. C. Dystrophic calcification, as present around the elbow and forearm here in this 10.5-year-old girl with juvenile dermatomyositis and anti-MJ autoantibodies, is seen in up to 25% of juvenile-onset dermatomyositis and less frequently in adult-onset disease. Calcinosis is present in > 60% of patients with the anti-MJ autoantibody phenotype. D. Lipodystrophy, loss of subcutaneous fat with frequently associated insulin resistance, diabetes and hypertriglyceridemia, are associated with juvenile-onset dermatomyositis. Generalized lipodystrophy, a widespread loss of fat from the trunk and extremities, has been associated with anti-p155 autoantibodies. A loss of fat from the arm is seen in this 20-year-old woman with juvenile onset dermatomyositis since age 8 years, who has anti-p155 autoantibodies and lipodystrophy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bohan A, Peter JB. Polymyositis and dermatomyositis. Parts 1 and 2. N Engl J Med. 1975;292:344–347. 3403–407. - PubMed
    1. Oddis CV, Rider LG, Reed AM, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum. 2005;52:2607–2615. - PubMed
    1. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008:2201–2212. - PubMed
    1. Oddis CV, Conte CG, Steen VD, Medsger TA., Jr Incidence of polymyositis-dermatomyositis: A 20-year study of hospital diagnosed cases in Allegheny County, PA 1963–1982. J Rheumatol. 1990;17:1329–1334. - PubMed
    1. Mendez EP, Lipton R, Ramsey-Goldman R, et al. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49:300–305. - PubMed

Publication types

Substances

  NODES
INTERN 3
twitter 2